Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasHodgkin LymphomaIndolent LymphomasradiotherapyDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupNodular lymphocyte-predominant (NLPHL)unfitICD10C81.-C82.-C82.7C82.9C83.1C83.3C84.4MeSHHodgkin DiseaseLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralSequenceBRNT1.8/DCRB375, Hodgkin, C1-12 (PID2364) -|- BRNT1.8/DCRB375 - BRNT1.8, C1-16 (PID2365).BRNT1.8/NIVO3, Hodgkin, C1 (PID1903) -|- C2-4 (PID1904)CheckMate 205: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (NIVO240/DOXO25/VNBL6/DCRB375), B (PID1375)NIVAHL Arm B: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (PID1970) -|- AVD (PID257)PAED EuroNet-PHL-C2, Hodgkin, TL-1PAED EuroNet-PHL-C2, Hodgkin, TL-2PAED EuroNet-PHL-C2, Hodgkin, TL-3PEMB200, Hodgkin, A (PID1969) -|- AVD (DOXO25/VNBL6/DCRB375), B (PID1962)PEMB200/ICE (ETOP100/CRBP5/IFOS5), Hodgkin, C1-2 (PID2691) -|- PEMB200, C3 (PID2692)PEMB200/LDOX15/GEMC1000/VINO20, Hodgkin (PID2024) -|- BRNT1.8, maint. (PID849)RITU375, Hodgkin, C1-4 (PID2360) -|- RITU375, maint., C5-8 (PID2361)ChemotherapyChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineChemo-substanceBendamustineBleomycinBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDacarbazineDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideGemcitabineIfosfamideMelphalanMethylprednisoloneNivolumabOxaliplatinPembrolizumabPrednisoloneProcarbazineRituximabVinblastineVincristineVinorelbineNo. Substances1234567 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances123456789Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityDose denseDose intensifiedhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceReinductionTherapy intentioncurativecurative or palliativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHematuriaHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNephritisNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisPainParesthesiaPneumoniaPruritusPyrexiaRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorAbali H Allen PBehringer KBorchmann PBryan LJBröckelmann PBöll BCencini EChen RCheson BDColwill RConnors JEichenauer DAEngert AFriedberg JW Gopal AGutierrez AHerrera AFHertzberg MSJosting AKumar AKörholz DLittle RLynch RCMoskowitz AJMoskowitz CO'Connor OAPrusila REIRamchandren RSantoro ATessoulin BWon YWYounes ADiseaseB-Non-Hodgkin-Lymphom/Hodgkin Lymphomfortgeschrittenes Hodgkin Lymphom, Stadium III-IV, Erstlinie, ECOG 0-2fortgeschrittenes klassisches Hodgkin Lymphom, Erstlinie, ECOG 0-1fortgeschrittenes oder early unfavorable Hodgkin Lymphom, Erstlinie, ECOG 0-1Hodgkin Lymphom, Erhaltung nach ASZT bei Patienten mit erhöhtem Rezidiv- oder Progressionsrisiko, ECOG 0-2Hodgkin Lymphom, Erstlinientherapie, >60 Jahre, ECOG 0-1Hodgkin Lymphom, NLPHL Stadium IA ohne RisikofaktorenHodgkin Lymphom, nodulär-lymphozytenprädominant (NLPHL)Hodgkin Lymphom, rezidiviert nach autologer Stammzelltransplantation, Ann Arbor II-IVHodgkin Lymphom, rezidiviert oder therapierefraktärHodgkin Lymphom, rezidiviert oder therapierefraktär, ECOG 0-3Hodgkin Lymphom, rezidiviert oder therapierefraktär, nach autologer SCT oder SCT ungeeignetHodgkin Lymphom, Stadium I-II, ErstlinieHodgkin Lymphom, Stadium IIb - IV, Erstlinie, 18-60 JahreHodgkin Lymphom, therapierefraktär oder rezidiviert, ECOG 0-1Hodgkin Lymphom, über 60 J., unfit, ECOG 0-3, ErstlinieHodgkin Lymphom Stadium IIb mit Risikofaktoren, Stadium III und IV, Erstlinie, 18-60 JahreHodgkin Lymphom Stadium I und II ohne RisikofaktorenHodgkin Lymphom Std. IIb mit Risikofaktoren, Std. III u IV, Erstlinie, 18-60 Jahreklassisches Hodgkin lymphom, early stage und unfavorable, ECOG 0-1klassisches Hodgkin Lymphom, Rezidiv nach ASZT und Brentuximab Vedotin, ECOG 0-1neudiagnostiziertes Hodgkin Lymphom, Ann Arbor stage IA-IIB, ECOG 0-2neu diagnostiziertes Hodgkin Lymphom, fortgeschritten, Alter 60-75, ECOG 0-2Neudiagnostiziertes Hodgkin Lymphom im Kindes- und JugendalterNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL)Nodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL), therapierefraktär oder rezidiviert, ECOG 0-1Non-Hodgkin-Lymphom / Hodgkin Lymphomprimär refraktäres oder rezidiviertes Hodgkin Lymphom, ECOG 0-2refraktäres oder rezidivierendes Hodgkin Lymphom, ECOG 0-1refraktäres oder rezidiviertes Hodgkin Lymphom, für eine Transplantation geeignet, ECOG 0-1rezidivierendes oder refraktäres Hodgkin Lymphom, 18-65 Jahre, ECOG 0-2rezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2Rezidiviertes oder refraktäres Hodgkin Lymphom, ECOG 0-1Rezidiviertes oder refraktäres Hodgkin Lymphom nach Hochdosis Chemotherapie und ASZT, ECOG 0-1OriginAnderson Cancer Center, The University of Texas MD, HoustonCenter for Lymphoid Malignancies, Columbia University Medical Center-College of Physicians and Surgeons, New York, NY, USACity of Hope National Medical Center, Duarte, CanadaDepartment of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, ECHELON-1Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, ItalyDivision of Hematology and Oncology, Georgia Cancer Center at Augusta University, AugustaEmory University Winship Cancer Institute, Atlanta, GAEuropean Network-Paediatric Hodgkin’s LymphomaStudy Group (EuroNet-PHL)German-Speaking Myeloma Multicenter Group, GMMG-HD6, GHSG-HD21 German Hodgkin Study Group (GHSG) German Hodgkin Study Group (GHSG), University Hospital of Cologne, HD 13German Hodgkin Study Group NIVAHL TrialHaematology Unit, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, ItalyHanyang University College of Medicine, Seoul, South KoreaKlinik für Innere Medizin, Universität KölnKlinik I für Innere Medizin, Universitätsklinikum KölnLymphoma Research Foundation, New York, USA, ACCRU trialMedical Oncology Unit, Mersin University, Mersin, TurkeyMemorial Sloan-Kettering Cancer Center, New York, NY, USAMemorial Sloan Kettering Cancer Center, KEYNOTE-087 investigatorsMemorial Sloan Kettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, AETHERA trialMemorial Sloan Kettering Cancer Center, New York, USANantes Medical University, Nantes, FranceNational Cancer Institute, Bethesda, USAService of Hematology, Son Espases University Hospital, Palma de Mallorca, SpainUniversity Hospital Cologne and University Hospital Münster, GermanyUniversity of Oulu, Oulu, FinlandUniversity of Tennessee, Knoxville, TN, Checkmate 205University of Toronto Autologous Bone Marrow Transplant Program, Toronto Hospital, CanadaUniversity of Washington, Seattle, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAWestmead Hospital, Westmead, AustraliaWilmot Cancer Institute, University of Rochester, Rochester, NY, USAProtocols in Revision 45 protocols foundProtocols under revision.ABVD - Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID472)BEACOPP Basis, Hodgkin Lymphoma (PID474)BEACOPP dosisescalated, Hodgkin Lymphoma (PID473)Bendamustine 120, Hodgkin Lymphoma (PID2395)Brentuximab Vedotin 1.8 / Bendamustine 90, Hodgkin Lymphoma (PID2363)Brentuximab Vedotin 1.8 / Cyclophosphamide 1250 / Doxorubicin 40 / Etoposide 150 / Dacarbazine 250 / Dexamethasone 40, Hodgkin Lymphoma (PID962)Brentuximab Vedotin 1.8 / Dacarbazine 375 - Brentuximab Vedotin 1.8, Hodgkin Lymphoma, Cycle 13-16 (PID2365)Brentuximab Vedotin 1.8 / Dacarbazine 375, Hodgkin Lymphoma, Cycle 1-12 (PID2364)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma (PID90)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 1 (PID1903)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 2-4 (PID1904)Brentuximab Vedotin 1.8, maintenance, Hodgkin Lymphoma (PID849)Brentuximab Vedotin 1.8, Hodgkin Lymphoma (PID475)BV-ICE - Brentuximab Vedotin 1.5 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, Hodgkin Lymphoma (PID1902)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, Hodgkin Lymphoma (PID1156)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2 / Radiation, Hodgkin Lymphoma (PID1951)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2, Hodgkin Lymphoma (PID587)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID257)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1962)ESHAOx - Etoposide 40 / Oxaliplatin 130 / Cytarabine 2000 / Methylprednisolone 500, Hodgkin Lymphoma (PID2347)GemOx - Gemcitabine 1000 / Oxaliplatin 100, Hodgkin Lymphoma (PID2382)ICE - Ifosfamide 1.33 / Carboplatin 5 / Etoposide 100, Hodgkin Lymphoma. (PID2380)Ifosfamide 2 / Gemcitabine 800 / Vinorelbine 20 / Prednisolone 100, Hodgkin Lymphoma (PID70)mini-BEAM - Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 30, Hodgkin Lymphoma (PID2381)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID1970)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1375)Nivolumab 240, Hodgkin Lymphoma (PID844)Nivolumab 240, Hodgkin Lymphoma, part A (PID1374)PAED EuroNet-PHL-C2, OEPA, Hodgkin Lymphoma (PID1280)Pembrolizumab 200 / Doxorubicin liposomal 15 / Gemcitabine 1000 / Vinorelbine 20, Hodgkin lymphoma (PID2024)Pembrolizumab 200 / ICE (Etoposide 100 / Carboplatin 5 / Ifosfamide 5) - Pembrolizumab 200, Hodgkin Lymphoma, Cycle 3 (PID2692)Pembrolizumab 200 / ICE (Etoposide 100 / Carboplatin 5 / Ifosfamide 5), Hodgkin Lymphoma, Cycle 1-2 (PID2691)Pembrolizumab 200, Hodgkin Lymphoma (PID1264)Pembrolizumab 200, Hodgkin Lymphoma, A (PID1969)Pembrolizumab 400, Hodgkin Lymphoma (PID1269)Prednisolone 40 / Vinblastine 6 / Doxorubicin 50 / Gemcitabine 1000, Hodgkin Lymphoma (PID1075)R- Benda - Rituximab 375 / Bendamustine 120, Hodgkin Lymphoma (PID2405)R-ABVD - Rituximab 375 / Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID2396)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 1.67, Hodgkin Lymphoma (PID2383)Rituximab 375, Hodgkin Lymphoma, maintenance, cycle 5-8 (PID2361)Rituximab 375, Hodgkin Lymphoma, Cycle 1-4 (PID2360)Vinblastine 6, Hodgkin Lymphoma (PID2331)
